ConductScience.org, home
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
API referenceFor AI assistants

Trial · NCT02605174

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 12 of 12

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPercentage of Participants Headache Pain Free at 2 Hours Post Dose2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable headache pain free data.percentage of participantsNUMBER
PRIMARYPercentage of Participants Who Are Most Bothersome Symptom (MBS) Free2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable MBS data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants With Headache Relief2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable headache relief data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDNumber of Participants With Headache RecurrenceFrom 2 Hours Post Dose Up to 48 HoursAll randomized participants who received at least one dose of study drug and had evaluable headache recurrence data.ParticipantsCOUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIEDPercentage of Participants Use of Rescue Medication2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants Use of Rescue MedicationFrom 2 Hours Post Dose Up to 24 HoursAll randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants Use of Rescue MedicationFrom 24 Post Dose Up to 48 HoursAll randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants Nausea Free2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable nausea free data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants With Phonophobia Free2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable phonophobia free data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants With Photophobia Free2 hours post doseAll randomized participants who received at least one dose of study drug and had evaluable photophobia free data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDPercentage of Participants With Resource Utilization6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine AttackAll randomized participants who had received at least one dose of study drug and had evaluable resource utilization data.percentage of participantsNUMBER
OTHER_PRE_SPECIFIEDNumber of Participants With Treatment Emergent EventsFrom Baseline Up to End of Study (Up to 11 Weeks)All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.participantsNUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02605174/outcomes

API referenceFor AI assistants